Hyperkalemia: A review

Journal of Intensive Care Medicine

Volumn 20, Issue 5, 2005, Pages 272-290

  Evans, Kimberley J ^a   Greenberg, Arthur ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Etiologies of hyperkalemia; Hyperkalemia; Potassium homeostasis; Treatment of hyperkalemia

Indexed keywords

ALDOSTERONE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CATECHOLAMINE DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; GLUCONATE CALCIUM; HEPARIN; HERBACEOUS AGENT; INDOMETACIN; INSULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PENTAMIDINE; PHENTOLAMINE; PHENYLEPHRINE; POTASSIUM; PROPRANOLOL; SALBUTAMOL; SPIRONOLACTONE; TACROLIMUS; TRIAMTERENE; TRIMETHOPRIM; UNINDEXED DRUG;

ACID BASE BALANCE; ALDOSTERONE RELEASE; DRUG MECHANISM; DRUG POTENTIATION; ECG ABNORMALITY; HEART ARRHYTHMIA; HOMEOSTASIS; HUMAN; HYPERKALEMIA; KIDNEY TUBULE EXCRETION; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; POTASSIUM INTAKE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT;

ALGORITHMS; HOMEOSTASIS; HUMANS; HYPERKALEMIA; KIDNEY DISEASES; POTASSIUM;

EID: 30544452999     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066605278969     Document Type: Review

References (146)

1. Davy H. Bakerian Lecture. Philosophical Transactions of the Royal Society. 1808;98:1-44.
2. Smith E.F. James Woodhouse: A Pioneer in Chemistry. Philadelphia, Pa: John C. Winston; 1918.
3. Greenberg A. Hyperkalemia: Treatment options. Semin Nephrol. 1998;18:46-57.
4. Forbes G, Lewis A. Total sodium, potassium and chloride in adult man. J Clin Invest. 1956;35:596-602.
5. Sterns R, Cox M, Feig P, Singer I. Internal potassium balance and the control of the plasma potassium concentration. Medicine. 1981;60:339-354.
6. Brown RS. Extrarenal potassium homeostasis. Kidney Int. 1986;30:116-127.
7. Clausen T, Everts M. Regulation of the Na K pump in skeletal muscles. Kidney Int. 1989;35:1-13.
8. Wright F, Giebisch G. Renal potassium transport: Contributions of individual nephron segments and populations. Am J Physiol. 1978;235:F515-F527.
9. Giebish G. A trail of research on potassium. Kidney Int. 2002;62:1498-1512.
10. Young DB, Smith MJ Jr, Jackson TE, Scott RE. Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone. Am J Physiol. 1984;247:E328-E335.
11. Basti C, Hayslett J. The cellular action of aldosterone in target epithelia. Kidney Int. 1992;42:250.
12. Panese S, Martin RS, Virginillo M, et al. Mechanism of enhanced transcellular potassium-secretion in man with chronic renal failure. Kidney Int. 1987;31:1377-1382.
13. Bia M, DeFronzo R. Extrarenal potassium homeostasis. Am J Physiol. 1981;240:F257-F268.
14. Muto S, Sansom S, Giebisch G. Effects of a high potassium diet on electrical properties of cortical collecting ducts from adrenalectomized rabbits. J Clin Invest. 1988;81:376-380.
15. Field M, Stanton B, Giebisch G. Influence of ADH on renal potassium handling: A micropuncture and microperfusion study. Kidney Int. 1984;25:502-511.
16. DeFronzo R, Bia M, Birkhead G. Epinephrine and potassium homeostasis. Kidney Int. 1981;20:83-91.
17. Salem M, Rosa R, Battle D. Extrarenal potassium tolerance in chronic renal failure: Implications for the treatment of acute hyperkalemia. Am J Kidney Dis. 1991;18:421-440.
18. Allon M, Shanklin N. Adrenergic modulation of extrarenal potassium disposal in men with end stage renal disease. Kidney Int. 1991;40:1103-1109.
19. Montoliu J, Lens X, Revert L. Potassium lowering effect of albuterol for hyperkalmeia in renal failure. Arch Intern Med. 1988;85:507-512.
20. Lens X, Montoliu J, Cases A, Campistol J, Revertt L. Treatment of hyperkalemia in renal failure: Salbutamol v. insulin. Nephrol Dial Transplant. 1989;4:228-232.
21. Liou H, Chiang S, Wu S, et al. Hypokalemic effects of intravenous infusion or nebulization of salbutamol in patients with chronic renal failure. Am J Kidney Dis. 1994;23:266-271.
22. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann Intern Med. 1989;110:426-429.
23. Brown M, Brown D, Murphy M. Hypokalemia from beta-receptor stimulation by circulating epinephrine. N Engl J Med. 1983;309:1414-1419.
24. DeFronzo R, Bia M, Birkhead G. Epinephrine and potassium homeostasis. Kidney Int. 1981;20:83-91.
25. Williams M, Rosa R, Silva P, Brown R, Epstein F. Impairment of extrarenal potassium disposal by alpha-adrenergic stimulation. N Engl J Med 1984;311:145-149.
26. Williams M, Gervino E, Rosa R, et al. Cathecholamine modulation of rapid potassium shifts during exercise. N Engl J Med. 1985;312:823-827.
27. Adrogue H, Madias N. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med. 1981;71:456.
28. Magner P, Robinson L, Halperin R. The plasma concentration in metabolic acidosis: A re-evaluation. Am J Kidney Dis. 1988;11:220.
29. Oster J, Perez G, Castro A, Vaamonde C. Plasma potassium response to acute metabolic acidosis induced by mineral and nonmineral acids. Miner Electrolyte Metab Mineral and Electrolyte Metabolism 1980;4:28-36 Mineral and Electrolyte Metabolism
30. Graber M. A model of the hyperkalemia produced by metabolic acidosis. Am J Kidney Dis. 1993;22:436-444.
31. Clark B, Brown R. Potassium homeostasis and hyperkalemic syndromes. Endacrinol Metab Clin North Am. 1995;24:573-591.
32. Hayslett J, Binder H. Mechanism of potassium adaptation. Editorial review. Am J Physiol. 1982;243:F103-F112.
33. Alexander E, Levinsky N. An extrarenal mechanism of potassium adaptation. J Clin Invest. 1968;47:740-748.
34. Sandle G, Gaiger E, Goodship T. Evidence for large intestinal control of potassium homeostasis in uremic patients undergoing long term dialysis. Clin Sci. 1987;73:247-252.
35. Kahn T, Kaji D, Nicolis G, Karkoff L, Stein R. Factors related to potassium transport in stable chronic renal disease. Clin Sci Molec Med. 1978;54:661
36. Widmer B, Gerhardt R, Harrington J, Cohen J. Serum electrolytes and acid base composition. The influence of graded degrees of chronic renal failure. Arch Intern Med. 1979;139:1099.
37. Acker C, Johnson J, Palevsky P, Greenberg A. Hyperkalemia in hospitalized patients. Arch Intern Med. 1998;158:917-924.
38. Moore M, Bailey R. Hyperkalemia in patients in the hospital. N Z Med J. 1989;102:557-558.
39. Shapiro S, Slone D, Lewis G, Jick H. Fatal dug reactions among medical inpatients. JAMA. 1971;216:467-472.
40. Paice B, Gray J, Mcbride D, Lawson D. Hyperkalemia in patients in hospital. Br Med J. 1983;286:1189-1192.
41. Ponce S, Jennings A, Madias N, Harrington J. Drug-induced hyperkalemia. Medicine. 1985;64:357-370.
42. Graber M, Subramani K, Corish D, Schwab A. Thrombocytosis elevates serum potassium. Am J Kidney Dis. 1988;12:116-120.
43. Rose B, Post T. Clinical Physiology of Acid-Base and. Electrolyte Disorders, 5th ed. New York, NY: McGraw-Hill; 2001.
44. Don B, Sebastian A, Cheitlin M, Christiansen M, Schambelan M. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med. 1990;322:1290-1292.
45. Ray K, Dorman S, Watson R. Severe hyperkalemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: A potentially life threatening interaction. J Hum Hypertens. 1999;717-720.
46. McCaughan D. Hazards of non-prescription potassium supplements. Lancet. 1984;1:513-514.
47. Miller L. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interaction. Arch Intern Med. 1998;158:2200-2211.
48. Perazella M. Drug induced hyperkalemia: Old culprits and new offenders. Am J Med. 2000;109:307-314.
49. Souilillou J, Fillaudeau F, Keribin J, Guenel J. Acute hyperkalemia risks in recipients of kidney graft cooled with Collins solution. Nephron. 1977;19:301-304.
50. Perez G, Oster J, Pelleya R, Caralis P, Kem D. Hyperkalemia from single small oral doses of potassium chloride. Nephron. 1984;36:270.
51. Lin M, Linton R, Wolff C, Band D. Propranolol, exercise, and arterial plasma potassium. Lancet. 1981;2:591.
52. Thomson A. Kelly D. Exercise stress-induced changes in systemic arterial potassium in angina pectoris. Am J Cardiol. 1989;63:1435-1440.
53. Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med. 1974;291:807.
54. Bywaters, EGL, Beall D. Crush injuries with impairment of renal function. Br Med J. 1941;1:427.
55. DeFronzo R, Cooke R, Goldberg M, Cox M, Myers A, Agus Z. Impaired renal tubular potassium secretion in systemic lupus erythematosus. Ann Intern Med. 1977;86:268-271
56. DeFronzo R, Taufield P, Black H, McPhedran P, Cooke C. Impaired renal tubular potassium secretion in sickle cell disease. Ann Intern Med. 1979;90:310-316.
57. Battle D, Arruda J, Kurtzman N. Hyperkalemic distal tubular acidosis associated with obstructive uropathy. N Engl J Med. 1981;304:373-380.
58. Perazella M, Mahnensmith M. Hyperkalemia in the elderly. J Gen Intern Med. 1997;12:646-656.
59. Ponce S, Jennings A, Madias N, Harrington J. Drug induced hyperkalemia. Medicine. 1985;64:357-370.
60. Chiu T, Billiard M, Chen J. Rapid life threatening hyperkalemia after addition of amilirode-HCL hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med. 1997;30:612-615.
61. Wan H, Lye M. Moduretic induced metabolic acidosis and hyperkalemia. Postgrad Med J. 1980;56:348.
62. Lee B, Medina I, Benowitz N, Jacob P, Wofsy C, Mills J. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med. 1989;110:606-611.
63. Reiser I, Chou S, Brown M, Porush J. Reversal of trimethoprim-induced anti-kalliuresis. Kidney Int. 1996;50:2063-2069.
64. Velaquez H, Perazella M, Wright F, Ellison D. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296-301.
65. Alappan R, Perazella M, Buller G. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1996;124:316-320.
66. Peltz S, Hashmi S. Pentamidine-induced severe hyperkalemia. Am J Med. 1989;87:698-699.
67. DeFronzo R. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 1980;17:118-134.
68. Tan S, Shapiro R. Franco R. Indomethacin-induced prostaglandin inhibition with hyperkalemia. Ann Intern Med. 1979;90:783-785.
69. Garella S, Matarese R. Renal effects of prostaglandins and clinical adverse effects of non-steroidal anti-inflammatory agents. Medicine. 1984;63:165-181.
70. Reardon L, Macpherson D. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: How much should you worry? Arch Intern Med. 1998;158:26-32.
71. Speiris C, Dolfrey C, Inman W, Rawson N, Wilton L. Post marketing surveillance of enalapril, II: Investigation of the potential role of enalapril in deaths with renal failure. Br Med J 1988;297:830-832.
72. Kostis J, Shelton B, Gosselin G et al. Adverse effects of enalapril in the studies of left ventricular dysfunction. Am Heart J. 1996;131:350-355.
73. Juurlink D, Mamdani M, Kopp A, Laupacis A, Redelmeier D. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-1658.
74. Bakris G, Siomas M, Bolton W. Differential effects of valsartan and lisnopril on potassium homeostasis in hypertensive patients with nephropathy. J Am Soc Nephrol. 1999;10:68A.
75. Savoy A, Palant C, Patchin G, Graettinger W. Losartan effects on serum and lisinopril in an elderly population. J Am Soc Nephrol. 1998;9:111A.
76. Appel G, Radhakrishnan J, Avram M, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care. 2003;26:1402-1407.
77. Knoll G, Sahgal A, Nair R. ACE inhibitors or angiotensin receptor blockers raise risk of hyperkalmeia in hemodialysis patients. Am J Med. 2002;112:110-114.
78. Bantle J, Nath K, Sutherland D, Najarian J, Ferris T. Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients. Arch Intern Med. 1985;145:505-508.
79. Jain A, Fung J, Todo S, et al. One thousand consecutive primary orthotopic liver transplants under FK506: Survival and adverse events. Transplant Proc. 1995;27:1099-1104.
80. Wilson ID, Goetz F. Selective hypoaldosteronism after prolonged heparin administration. Am J Med. 1964;36:635-640.
81. Oster J, Singer I, Fishman L. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98:575-586.
82. Canova C, Fischler M, Reinhart W. Effect of low-molecular weight heparin on serum potassium. Lancet. 1997;349:1447-1448.
83. Levesque H, Verdier S, Cailleuxx N, et al. Low molecular weight heparins and hypoaldosteronism. Br Med. J. 1990;300:1437-1438.
84. Vilberti G. Glucose induced hyperkalemia: A hazard for diabetics? Lancet. 1978;1:690.
85. Nicolis G, Kahn T, Sanchez A, Gabrilove L. Glucose-induced hyperkalemia in diabetic subjects. Arch Intern Med. 1981;141:39-53.
86. Montoliu J, Revert L. Lethal hyperkalemia associated with severe hyperglycemia in diabetic patients with renal failure. Am J Kidney Dis. 1985;1:47-48.
87. Sargent A, Overton C, Kuwik R, Varcelott J, Deppe S. Octreotide induced hyperkalemia. Pharmacotherapy. 1994;14:497-501.
88. Bushinsky D, Gennari F. Life threatening hyperkalemia induced by arginine. Ann Intern Med. 1978;89:632-634.
89. Dickerman H, Walker W. Effect of cationic amino acids infusion on potassium metabolism in vivo. Am J Physiol. 1964;206:403-408.
90. Gronert G, Theye R. Pathophysiology of hyperkalemia induced succinylcholine. Anesthesiology. 1975;43:88-89.
91. Stevenson P, Birch A. Succinylcholine induced hyperkalemia in a patient with a closed head injury. Anesthesiology. 1979;51:89-90.
92. Cooperman L. Succinylcholine induced hyperkalemia in neuromuscular disease. JAMA. 1970;213:1867-1871.
93. Bismuth C, Gaultieer M, Conso F, Efthymious M. Hyperkalemia in acute digitalis poisoning: Prognostic significance and therapeutic implications. Clin Toxicol. 1973;6:153-162.
94. Papadakis M, Wexman M, Fraser C, Sedlacek S. Hyperkalemia complicating digoxin toxicity in a patient with renal failure. Am J Kidney Dis. 1985;5:64-66.
95. Moreno M, Murphy C, Goldsmith C. Increase in serum potassium resulting from the administration of hypertonic mannitol and other solutions. J Clin Lab Med. 1969;73:291-298.
96. Saltin B, Blomqvist G, Mitchel J, Wildenthal K, Chapman C. Response to exercise after bed rest and after training. Circulation. 1968;(suppl 7):1-78.
97. Norgaard A, Botker H, Klitgaard N, Toft P. Digitalis enhances exercise induced hyperkalemia. Eur J Clin Pharmacol. 1991;41:609-611.
98. Castellino P, Bia M, DeFronzo R. Adrenergic modulation of potassium metabolism in uremia. Kidney Int. 1990;37:773-798.
99. Lundborg P. The effect of adrenergic blockade on potassium concentrations in different conditions. Acta Med Scand. 1983;672(suppl):121-132.
100. Arthur S, Greenberg A. Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. Clin Nephrol. 1990;33:269-271.
101. Hamad A, Salameh M, Zihlif M, Feinfield D, Carvounis C. Life-threatening hyperkalemia after intravenous labetolol injection for hypertensive emergency in a hemodialysis patient. Am J Nephrol. 2001;21:241-244.
102. Swenson E. Severe hyperkalemia as a complication of Timolol, a topically applied -adrenergic antagonist. Arch Intern Med. 1986;146:1220-1221.
103. Fontaine B, Lapie P, Plassart E, et al. Periodic paralysis and voltage-gated ion channels. Kidney Int. 1996;49:9-18.
104. Rimmer J, Horm J, Gennari F Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147:867-869.
105. Ettinger P, Regan T, Oldewurtel H. Hyperkalemia, cardiac conduction, and the electrocardiogram: A review. Am Heart J. 1974;88:360-371.
106. Surawicz B. Relationship between electrocardiogram and electrolytes. Am Heart J. 1967;73:814-834.
107. Surawicz B, Chlebus H, Mazzoleni A. Hemodynamic and electrocardiographic effects of hyperpotassemia. Differences in response to slow and rapid increases in concentration of plasma K. Am Heart J. 1967;73:647-664.
108. Allon M. Medical and dialytic management of hyperkalemia in hemodialysis patients. Int J Artif Organs. 1996;19:697-699.
109. Szerlip H, Weiss J, Singer I. Profound hyperkalemia without electrocardiographic manifestations. Am Kidney Dis. 1986;7:461-465.
110. Freeman S, Fale A: Muscular paralysis and ventilatory failure caused by hyperkalemia. Br J Anaesthesiol. 1993;70:226-227.
111. Dietrich K, Walls R. Hyperkalemia: ECG manifestations and clinical considerations. J Emerg. Med. 1986;4:449-455.
112. Bower J, Mengle H. The additive effects of digitalis. A warning with report of two deaths. JAMA. 1936;106:1151-1153.
113. Fenton F, Smally A, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med. 1996;28:440-441.
114. Brenner & Rector's The Kidney. 6th ed. Philadelphia, PA, Saunders; 2000.
115. Nola G, Pope S, Harrison D. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79:499-507.
116. Defronzo R, Felig P, Ferrannini E, Wahren J. Effects of graded doses of insulin on splanchnic and peripheral potassium metabolism in man. Am J Physiol. 1980;238:E421-E427.
117. Alvestrand A, Wahren J, Smith D, Defronzo R. Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol. 1984;246:E174-E180.
118. Allon M, Dansby L, Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end stage renal disease. Am J Med. 1993;94:475-482.
119. Allon M. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis. 1996;28:508-514.
120. Kim H. Combined effects of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease. Nephron. 1996;72:476-482.
121. Ngugi N, McLigeyo S, Kayima J. Treatment of hyperkalemia by altering the transcellular gradient in patients with renal failure: efficacy of various therapeutic approaches. East Afr Med J. 1997;74:503-509.
122. Blumberg A, Weidmann P, Shaw S, Gnadinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988;85:507-512.
123. Evans K, Reddan D, Szczech L. Nondialytic management of hyperkalemia and pulmonary edema among end-stage renal disease patients: An evaluation of the evidence. Semin Dialysis. 2004;17:22-29.
124. Goldfarb S, Cox M, Singer I, Goldberg M. Acute hyperkalemia induced by hyperglycemia: hormonal mechanisms. Ann Intern Med. 1976;84:426-432.
125. Montoliu J, Revert L. Lethal hyperkalemia associated with severe hyperglycemia in diabetic patients with renal failure. Am J Kidney Dis. 1985;5:47-48.
126. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38:869-872.
127. Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metered dose inhaler with spacer for hyperkalemia. Chest. 1999;115:617-622.
128. Montoliu J, Almirall J, Ponz E, Campistol J, Revert L. Treatment of hyperkalemia in renal failure with salbutamol inhalation. J Intern Med. 1990;228:35-37.
129. Mocan M, Mocan G, Mocan H, Gorcin B. Inhaler salbutamol for acute hyperkalemia. Isr J Med Sci. 1993;29:39-41.
130. Campese V, Ramoff M, Levitan D, Saglikes Y, Friedler R, Massry S. Mechanism of autonomic nervous system dysfunction in uremia. Kidney Int. 1981;20:246-253.
131. Burnell J, Villamil M, Uyeno B. The effect in humans of extracellular pH change on the relationship between serum potassium concentration and intracellular potassium. J Clin Invest. 1956;35:953-939.
132. Fenn W, Cobb D. The potassium equilibrium in muscle. J Gen Physiol. 1956;17:629-656.
133. Fulop M. Serum potassium in lactic acidosis and Ketoacidosis. N Engl J Med. 1979;300:1087.
134. Schwarz K, Burton D, Lubash G. Severe acidosis and hyperpotassemia with sodium bicarbonate infusion. Circulation. 1959;19:215-220.
135. Ahee P, Crowe A. The management of hyperkalemia in the emergency department. Journal of Accidental Emergency Medicine Accidental Emergency Medicine 2000;17:188-191.
136. Fraley D, Adler S. Correction of hyperkalemia by bicarbonate despite constant blood pH. Kidney Int. 1977;12:354-360.
137. Iqbal Z, Friedman E. Preferred therapy of hyperkalemia in renal insufficiency: Survey of nephrology training program directors (letter). N Engl J Med. Accidental Emergency Medicine 1989;320:60-61 Accidental Emergency Medicine
138. Gutierrez R, Schlessinger F, Oster J, Rietberg B, Perez G. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab. 1991;17:297-302.
139. Scherr L, Ogden D, Mead A. Management of hyperkalemia with a cation-exchange resin. N Engl J Med. 1961;264:115-119.
140. Lillemoe K, Romolo J, Hamilton S, Pennington L, Burdick J, Williams G. Intestinal necrosis due to sodium polystyrene (Kaxeylate) in sorbitol enemas: Clinical and experimental support for the hypothesis. Surgery. 1987;101:267-272.
141. Gruy-Kapral C, Emmett M, Santa C, Porter J, Fordtran J, Fine K. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol. 1998;9:1924-1930.
142. Flinn R, Merrill J, Welzant W. Treatment of the oliguric patient with a new sodium-exchange resin and sorbitol, a preliminary report. N Engl J Med. 1961;264:111-.
143. Blumberg A, Roser H, Zehnder C, Muller-Brand J. Plasma potassium in patients with terminal renal failure during and after haemodialysis: Relationship with dialytic potassium removal and total body potassium. Nephrol Dial Transplant. 1997;12:1629-1634.
144. Hou S, McElroy P, Nootens J, Beach M. Safety and efficacy of low-potassium dialysate. Am J Kidney Dis. 1989;13:137-143.
145. Allon M, Shanklin N. Effect of albuterol treatment on subsequent dialytic potassium removal. Am J Kidney Dis. 1995;26:607-613.
146. Feig P, Shook A, Sterns R. Effect of potassium removal during hemodialysis on the plasma potassium concentration. Nephron. 1981;27:25-30.